It's all in the hands of the CRO, Simbec-Orion now. Simbec-Orion only formed in 2014 and is trying to build its reputation as a boutique, full service CRO. As far as I know, it has picked up two phase III trials since it was launched, one in cancer with a French pharma. and the Lupuzor trial. These trials will be high profile for Simbec. They'll want to perform as well as they possibly can and that will include meeting recruitment targets. I believe they also took part in the recent fundraising so have a slice of the pie too.
Having said all of that, I seem to remember reading somewhere that around 80% of clinical trials miss recruitment targets. Let's hope we're in the 20% - time will tell!!
Thankyou for clarifying that, So with 24 centres now recruiting? Approx 8 patients per centre, And i would assume the american sites would find it easy to get a higher number than this, If the sites all specialise in lupus, in my opinion i cant see why we will not have the recruitment in place this year,
200 patients in total, randomly assigned to receive either Lupuzor or a placebo (plus standard of care treatment). So in effect roughly 100 should be allocated to the treatment arm and 100 to the control arm.
To be honest I'm a little surprised that they are not reporting the progress of patient recruitment - on one hand you can say what does it matter? However with the lanstead deal the higher the sp the more remuneration they receive. Do you know if that is capped after way, say 10% more of less?
With the non-movement of the sp in recent weeks, do you think lanstead are selling? We've consolidated 30s now, and with so few shares in free float, coupled with limited selling from pi. I was wondering where mm were getting shares from.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.